Mereo BioPharma Group (Mereo BioPharma Group) Total Long-Term Liabilities : $6.48 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Mereo BioPharma Group Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Mereo BioPharma Group's Total Long-Term Liabilities for the quarter that ended in Dec. 2023 was $6.48 Mil.

Mereo BioPharma Group Total Long-Term Liabilities Historical Data

The historical data trend for Mereo BioPharma Group's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Total Long-Term Liabilities Chart

Mereo BioPharma Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Long-Term Liabilities

Get a 7-Day Free Trial

21.39

94.52

34.92

1.64

6.48

Mereo BioPharma Group Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Long-Term Liabilities	Get a 7-Day Free Trial												34.92	3.94	1.64	6.86	6.48

Mereo BioPharma Group Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Mereo BioPharma Group Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group (Mereo BioPharma Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (NAS:MREO) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

MAH0:Germany MAH0:Germany

Address

One Cavendish Place, 4th Floor, London, GBR, W1G 0QF

Website

https://www.mereobiopharma.com

Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.